article thumbnail

Unlocking the Potential of Healthcare Claims Data Part II: Optimizing Network Performance

Clarify Health

In the era of digital transformation, healthcare claims data stands out as a critical asset health plans can use to optimize their network performance. As value-based care models become the prevailing standard among leading-edge healthcare providers, payers must meet the moment with data-driven decision-making.

article thumbnail

Putting Patients First: Improving the Pharmaceutical Supply Chain

Impetus Digital

Safety and Quality Control The safety and quality of medications are paramount when it comes to patient care. This includes manufacturers, distributors, government agencies, healthcare providers , and other industry players, all of whom can positively or negatively influence the pharmaceutical supply chain.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Mastering the Art of Presentation: Choosing the Perfect Sample Bag for Pharma Sales Success

Contrarian Sales Techniques

Far from being just a means of transport, it’s a multi-faceted asset that elevates the art of salesmanship through organization, durability, security, and professional presentation. Ease of Transport: Comfort and Convenience Sales reps are often on the move, so ease of transport is a critical feature.

Sales 52
article thumbnail

A Primer on Telepharmacy

Nixon Gwilt Law

In this article, you will gain a high-level understanding of telepharmacy and how you can use and implement telepharmacy to positively impact patients, pharmacies, and healthcare providers. In addition, like telehealth, telepharmacy can contribute to health equity.

Medical 52
article thumbnail

Meet the company on a mission to transform research and advance healthcare

Pharmaceutical Technology

On the other hand, a lack of diversity in clinical trial populations, particularly when the disease population is significantly underrepresented, greatly diminishes the quality of data obtained for drug safety and efficacy profiles. This may sound obvious, but it is still a major hurdle in drug development.